Literature DB >> 28506000

Therapeutic effects of oral dimethyl fumarate on stroke induced by middle cerebral artery occlusion: An animal experimental study.

Anahid Safari1,2, Mehdi Fazeli2, Mohammad Reza Namavar3,4,5, Nader Tanideh6,7, Peyman Jafari8, Afshin Borhani-Haghighi3,9.   

Abstract

BACKGROUND: Dimethyl fumarate (DMF) has immune-modulatory and neuro-protective characteristics that can be used for treatment of acute ischemic stroke.
OBJECTIVE: To investigate the therapeutic effects of DMF on histological and functional recovery of rats after transient middle cerebral artery (MCA) occlusion.
METHODS: 22 Sprague-Dawley male rats weighing 275-300 g were randomized into three groups by block randomization. In the sham group (n = 7), the neck was opened, but neither MCA was occluded, nor any drug was administered.The control group (n = 7) was treated with vehicle (methocel) by gavage for 14 days after MCA occlusion. In the DMF-treated group (n = 8), treatment was performed with 15 mg/kg body weight dimethyl fumarate twice a day for 14 days after MCA occlusion. Transient occlusion of the right MCA was performed by intraluminal thread method in the DMF-treated and the control group. Neurological deficit score (NDS), pole test, and adhesive removal test were performed before the surgery, and on post-operative Days 0, 3, 5, 7, 10, and 14. After the final behaviour test, the animals' brains were perfused and removed. Brains were frozen and sectioned serially and coronally using a cryostat. Infract volume and brain volume were estimated by stereology.
RESULTS: The percentage of infarct volume was significantly lower in DMF-treated animals (5.76%) than in the control group (22.39%) (P < 0.0001). Regarding behavioural tests, the DMF-treated group showed better function in NDS on Days 7 (P = 0.041) and 10 (P = 0.046), but not in pole and adhesive removal tests. There was no significant correlation between behavioural tests and histological results.
CONCLUSION: Dimethyl fumarate could be beneficial as a potential neuroprotective agent in the treatment of stroke.

Entities:  

Keywords:  Cerebrovascular accident; Stroke; dimethyl fumarate; middle cerebral artery occlusion; neuroprotection

Mesh:

Substances:

Year:  2017        PMID: 28506000     DOI: 10.3233/RNN-160670

Source DB:  PubMed          Journal:  Restor Neurol Neurosci        ISSN: 0922-6028            Impact factor:   2.406


  5 in total

1.  Effects of nicorandil on neurobehavioral function, BBB integrity, edema and stereological parameters of the brain in the sub-acute phase of stroke in a rat model.

Authors:  Maryam Owjfard; Mohammad Reza Bigdeli; Anahid Safari; Mohammad Reza Namavar
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

2.  Neuroprotective effect of dimethyl fumarate in stroke: The role of nuclear factor erythroid 2-related factor 2.

Authors:  Anahid Safari; Hamzeh Badeli-Sarkala; Mohammad Reza Namavar; Elias Kargar-Abarghouei; Neda Anssari; Sadegh Izadi; Afshin Borhani-Haghighi
Journal:  Iran J Neurol       Date:  2019-07-06

3.  Neuroprotective effect of dimethyl fumarate on cognitive impairment induced by ischemic stroke.

Authors:  Xiaowen Hou; Haibin Xu; Wanli Chen; Nannan Zhang; Ziai Zhao; Xin Fang; Xing Zhang; Huisheng Chen; Yuanyuan Xu
Journal:  Ann Transl Med       Date:  2020-03

4.  Epidermal neural crest stem cell transplantation as a promising therapeutic strategy for ischemic stroke.

Authors:  Mohammad Saied Salehi; Sareh Pandamooz; Anahid Safari; Benjamin Jurek; Amin Tamadon; Mohammad Reza Namavar; Mehdi Dianatpour; Leila Dargahi; Negar Azarpira; Sadegh Fattahi; Seyed Mostafa Shid Moosavi; Somaye Keshavarz; Zahra Khodabandeh; Shahrokh Zare; Somayeh Nazari; Mojdeh Heidari; Sadegh Izadi; Maryam Poursadeghfard; Afshin Borhani-Haghighi
Journal:  CNS Neurosci Ther       Date:  2020-04-12       Impact factor: 5.243

Review 5.  Immunotherapy of experimental and human stroke with agents approved for multiple sclerosis: a systematic review.

Authors:  Mirjam Dreikorn; Zeljko Milacic; Vladimir Pavlovic; Sven G Meuth; Christoph Kleinschnitz; Peter Kraft
Journal:  Ther Adv Neurol Disord       Date:  2018-04-20       Impact factor: 6.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.